| Description | A number of 17-phenyl trinor prostaglandin F2α(17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma.1,2,3Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects.417-trifluoromethylphenyl-13,14-dihydro trinor PGF2αbears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester). As an ocular hypotensive agent, it would be expected that 17-trifluoromethylphenyl-13,14-dihydro trinor PGF2αwould act very much like the free acid of latanoprost. |
| Synonyms | 17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α |
| molecular weight | 458.518 |
| Molecular formula | C24H33F3O5 |
| CAS | 294856-01-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMF: 30 mg/mL Ethanol: 50 mg/mL PBS (pH 7.2): 1 mg/mL DMSO: 25 mg/mL |
| References | 1. Woodward, D.F., Krauss, A.H.P., Chen, J., et al.The pharmacology of Bimatoprost (LumiganTM)Survey of Ophthalmology45S337-S345(2001) 2. Stjernschantz, J.W.From PGF2α-isopropyl ester to latanoprost: A review of the development of xalatan. The proper lectureInvestigative Ophthalmology & Visual Science42(6)1134-1145(2001) 3. Sorbera, L.A., and Casta?er, J.TravoprostDrugs Future25(1)41-45(2000) 4. Resul, B., Stjernschantz, J., No, K., et al.Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agentsJournal of Medicinal Chemistry36243-248(1993) |
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α
CAS No.: 294856-01-2
A number of 17-phenyl trinor prostaglandin F2α(17-phenyl trinor PGF2α) derivatives have been approved for the treatmen
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.